Evidence map›Paper›PMID 34079821›Full record

ArticleFrontiers in molecular biosciences2021

Perspective: Humanized Pig Models of Bladder Cancer.

Natália Vieira Segatto, Camila Bonemann Bender, Fabiana Kommling Seixas, Kyle Schachtschneider, Lawrence Schook, Noah Robertson, Aisha Qazi, Maximillian Carlino, Luke Jordan, Courtni Bolt and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Journal of biomedical optics · 2025
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Natália Vieira SegattoPostgraduate Program in Biotechnology, Cancer Biotechnology Laboratory, Technology Development Center, Federal University of Pelotas, Pelotas, Brazil.
Camila Bonemann BenderPostgraduate Program in Biotechnology, Cancer Biotechnology Laboratory, Technology Development Center, Federal University of Pelotas, Pelotas, Brazil.
Fabiana Kommling SeixasPostgraduate Program in Biotechnology, Cancer Biotechnology Laboratory, Technology Development Center, Federal University of Pelotas, Pelotas, Brazil.
Kyle SchachtschneiderDepartment of Radiology, University of Illinois at Chicago, Chicago, IL, United States.
Lawrence SchookDepartment of Radiology, University of Illinois at Chicago, Chicago, IL, United States.
Noah RobertsonAlbion College, Albion, MI, United States.
Aisha QaziDepartment of Animal Sciences, University of Illinois at Urbana-Champaign, Urbana, IL, United States.
Maximillian CarlinoDepartment of Radiology, University of Illinois at Chicago, Chicago, IL, United States.
Luke JordanDepartment of Animal Sciences, University of Illinois at Urbana-Champaign, Urbana, IL, United States.
Courtni BoltDepartment of Animal Sciences, University of Illinois at Urbana-Champaign, Urbana, IL, United States.
Tiago CollaresPostgraduate Program in Biotechnology, Cancer Biotechnology Laboratory, Technology Development Center, Federal University of Pelotas, Pelotas, Brazil.
University of Illinois Urbana-Champaign · USUniversidade Federal de Pelotas · BRAlbion College · USUniversity of Illinois Chicago · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder cancer (BC) is the 10th most common neoplasia worldwide and holds expensive treatment costs due to its high recurrence rates, resistance to therapy and the need for lifelong surveillance. Thus, it is necessary to improve the current therapy options and identify more effective treatments for BC. Biological models capable of recapitulating the characteristics of human BC pathology are essential in evaluating the effectiveness of new therapies. Currently, the most commonly used BC models are experimentally induced murine models and spontaneous canine models, which are either insufficient due to their small size and inability to translate results to clinical basis (murine models) or rarely spontaneously observed BC (canine models). Pigs represent a potentially useful animal for the development of personalized tumors due to their size, anatomy, physiology, metabolism, immunity, and genetics similar to humans and the ability to experimentally induce tumors. Pigs have emerged as suitable biomedical models for several human diseases. In this sense, the present perspective focuses on the genetic basis for BC; presents current BC animal models available along with their limitations; and proposes the pig as an adequate animal to develop humanized large animal models of BC. Genetic alterations commonly found in human BC can be explored to create genetically defined porcine models, including the BC driver mutations observed in the FGFR3, PIK3CA, PTEN, RB1, HRAS, and TP53 genes. The development of such robust models for BC has great value in the study of pathology and the screening of new therapeutic and diagnostic approaches to the disease.

Indexed as

bladder cancerlarge animal modeloncopigpigurothelial carcinoma

Identifiers

PMID34079821
PMCPMC8165235
OpenAlexW3163350241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.